



FOR IMMEDIATE RELEASE

Date: 05 September, 2013

SomantiX B.V. and InterNA Technologies B.V. obtain a MIT R&D collaboration grant

Utrecht/Nijmegen (the Netherlands) – SomantiX B.V, a biotech company focusing on the development of tumor blood vessel targeting angiogenesis inhibitors, and InterNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, have received a so-called MIT grant ('MKB Innovatiestimulerend Topsectoren') within the Topsector Life Science & Health to develop a new cancer drug. The two companies will develop antibody-coated nanoparticles targeting anti-angiogenic miRNAs specifically to the tumor vasculature in renal cell cancer.

The funding of € 150,000 is granted by Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. The MIT program grants are aimed at funding collaborations between SMEs focusing on the development of innovative products, production processes or services.

Markwin Velders CEO of SomantiX said: "This award confirms the strength of SomantiX' target identification platform. It allows the targeting of different drug classes. The combination with InterNA's novel microRNAs will open new opportunities for cancer drug development".

"This MIT grant further exemplifies that our platform delivers bona fide miRNA drug candidates and provides us the resources for further validation in animal models for renal cell cancer. The vasculature targeted drug delivery of the unique anti-angiogenic miRNAs identified represents an innovative approach in the therapeutic intervention of this most common form of kidney cancer of which the incidence is still increasing", said Roel Schaapveld, CEO of InterNA Technologies.

About SomantiX

SomantiX is a Dutch biotech company founded in 2008 by Aglaia Oncology Seed Fund. SomantiX focuses on the development of agents for imaging and therapy of solid cancers through targeting of tumor blood vessels. SomantiX R&D programs focus on target discovery and validation and drug development.

See for more information www.somantix.com



About InterRNA Technologies B.V.

InterRNA Technologies develops cancer therapeutics based on a broadly applicable proprietary technology platform for the rapid identification and validation of therapeutic miRNAs. The Company has exclusive access to one of the largest miRNA libraries in the world. At present, InterRNA has established in vivo proof of concept for multiple pipeline candidates. The Company is pursuing a proactive partnership strategy to acquire appropriate delivery technologies for its products and expects to engage in corporate partnerships to progress several of its products into clinical development.

InterRNA Technologies was incorporated in December 2006 by Aglaia Oncology Fund as a spin-off from the Hubrecht Institute, Utrecht, the Netherlands.

See for more information www.interna-technologies.com.

Contacts:

Markwin Velders, PhD
CEO SomantiX B.V.
Padualaan 8
Hugo R. Kruyt building
Floor 8, Room O.807
3584 CH Utrecht
The Netherlands
Phone: +31 (0)30-7600976
E-mail: Velders@somantix.com

Roel Schaapveld, PhD, MBA
CEO InterRNA Technologies B.V.
Corporate office
Nijmegen City Centre
Jonkerbosplein 52
6534 AB Nijmegen
The Netherlands
Phone: +31 (0)24 352 96 33 / +31 (0)30 2532386
E-mail: schaapveld@interna-technologies.com